WRIB 2025: Innovative Strategy for Overcoming pH-Related Assay Variation in the Development and Validation of a Pharmacokinetic Assay for OBI-992, a TROP2-Targeting Exatecan-Based Antibody-Drug Conjugate, in Human Serum

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company*

State*

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.

Resources to Consider